Hong Kong 6/18/18—The South China Morning Post reports that DNA sequencer firm Oxford Nanopore Technologies is considering listing on the London and Hong Kong stock exchanges. The listing would take place next year or in 2020. According to the article, Oxford Nanopore’s revenues totaled £13.8 million ($17.9 million at £0.78 = $1) in 2017 (see Bottom Line). China represents 10%–15% of company sales presently but is expected to become the company’s largest market, according to the article.

According to a regulatory filing, the company reported cash and cash equivalents of £57.8 million ($741. million) as of March 31, which was prior to its latest funding raising (see IBO 3/31/18). The US accounted for the majority of company sales last year (39%), followed by Europe excluding the UK (31%), Rest of World (16%) and the UK (14%). However, Rest of World sales grew the fastest, up 432.4%. European and US sales rose 195.8% and 155.6%, whle UK sales were up 94.9%. The company’s average number of employees totaled 343.